Pharma Pulse: Tariffs, a Ceasefire, and Patient Access

Key Takeaways

• 100% tariff on imported APIs pushes firms toward US onshoring
• 20% transitional rate for companies with onshoring plan, no MFN
• 14‑day US‑Iran ceasefire temporarily stabilizes supply of amoxicillin and doxycycline
• Novo Nordisk’s Wegovy HD costs $399/month, delivers 21% average weight loss
• Survey shows only 18% of patients feel access improved, providers remain optimistic

Pulse Analysis

The new 100% tariff on imported active pharmaceutical ingredients (APIs) and patented drugs marks a decisive shift in U.S. trade policy aimed at bolstering domestic manufacturing. By tying tariff relief to either a most‑favored‑nation pricing pact or a Commerce‑approved onshoring plan, regulators are creating a financial incentive for companies to relocate production stateside. This could accelerate investment in U.S. facilities, but also raise short‑term costs for firms that must redesign supply chains or absorb higher import duties during the transition period.

Geopolitical risk resurfaced with a fragile 14‑day ceasefire between the United States and Iran, temporarily easing tension in the Strait of Hormuz—a critical conduit for petroleum‑derived inputs used in drug synthesis. The truce is especially significant for products like amoxicillin suspension and doxycycline capsules, where the Middle East supplies a sizable share of global output. While the pause offers short‑term stability, any resurgence of conflict could again disrupt raw‑material flows, underscoring the need for diversified sourcing strategies and strategic stockpiles.

On the commercial front, Novo Nordisk’s introduction of Wegovy HD—a 7.2 mg semaglutide injection priced at roughly $399 per month—adds a higher‑dose option for obesity management, backed by trial data showing a 21% average weight reduction. However, broader patient‑access challenges persist, as highlighted by the Experian Health survey: only 18% of patients feel access has improved, despite provider optimism. Staffing shortages, prior authorizations, and rising out‑of‑pocket costs continue to delay appointments, suggesting that policy and pricing changes alone won’t resolve systemic access gaps.